ID   BT474 A3
AC   CVCL_YX79
SY   BT474-A3
DR   cancercelllines; CVCL_YX79
DR   Wikidata; Q93432844
RX   PubMed=20386540;
CC   Population: Caucasian.
CC   Sequence variation: Gene fusion; HGNC; HGNC:24618; AHCTF1 + HGNC; HGNC:736; NAAA; Name(s)=AHCTF1-NAAA (from parent cell line).
CC   Sequence variation: Gene fusion; HGNC; HGNC:16173; DOK5 + HGNC; HGNC:17579; STARD3; Name(s)=STARD3-DOK5 (from parent cell line).
CC   Sequence variation: Gene fusion; HGNC; HGNC:13178; IKZF3 + HGNC; HGNC:12649; VAPB; Name(s)=VAPB-IKZF3 (from parent cell line).
CC   Sequence variation: Gene fusion; HGNC; HGNC:16651; MRPL45 + HGNC; HGNC:16181; TRPC4AP; Name(s)=TRPC4AP-MRPL45 (from parent cell line).
CC   Sequence variation: Gene fusion; HGNC; HGNC:7609; MYO9B + HGNC; HGNC:9764; RAB22A; Name(s)=RAB22A-MYO9B (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:1101; BRCA2; Simple; p.Ser3094Ter (c.9281C>A); ClinVar=VCV000188440; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11621; HNF1A; Simple; p.Gln495Ter (c.1483C>T); ClinVar=VCV000586785; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:6871; MAPK1; Simple; p.His61Gln (c.183C>G); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.Lys111Asn (c.333G>C); ClinVar=VCV000376483; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (from parent cell line).
CC   Genetic integration: Method=Transfection/transduction; Gene=HGNC; HGNC:2594; CYP19A1.
CC   Genetic integration: Method=Transfection/transduction; Gene=UniProtKB; P00552; Transposon Tn5 neo.
CC   Derived from site: In situ; Breast; UBERON=UBERON_0000310.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0179 ! BT-474
SX   Female
AG   60Y
CA   Cancer cell line
DT   Created: 12-03-20; Last updated: 10-04-25; Version: 10
//
RX   PubMed=20386540; DOI=10.1038/sj.bjc.6605641; PMCID=PMC2856013;
RA   Evans A.H., Pancholi S., Farmer I., Thornhill A., Evans D.B.,
RA   Johnston S.R.D., Dowsett M., Martin L.-A.;
RT   "EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in
RT   HER2/ER-positive breast cancer cells but functions synergistically
RT   with endocrine therapy.";
RL   Br. J. Cancer 102:1235-1243(2010).
//